Skip to main content
SpringerLink
Log in

The Role of Tissue Plasminogen Activator in Myocardial Infarction

  • Chapter
Acute Coronary Care 1987

Part of the book series: Acute Coronary Care Updates ((ACCU,volume 2))

Abstract

Although intravenous streptokinase has been available for over 25 years, the demonstration that emergency coronary arteriography is feasible during myocardial infarction has led to a resurgence of enthusiasm for thrombolytic therapy. In the 7 years since the documentation of the importance of thrombosis in myocardial infarction by DeWood et al (1), therapy has evolved from intracoronary streptokinase to intravenous streptokinase to intravenous clot-selective agents, including recombinant tissue-type plasminogen activator (t-PA). In this chapter, we will review the properties of t-PA as they relate to the enzyme’s clinical efficacy in acute myocardial infarction, adverse effects, and prospects for future use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897–902, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Collen D: Systemic thrombolytic therapy of acute myocardial infarction? Circulation 68:462–465, 1983.

    Article  PubMed  CAS  Google Scholar 

  3. Burket MW, Smith MR, Walsh TE, Brewster PS, Fraker TD: Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state. Am J Cardiol 56: 441–444, 1985.

    Article  PubMed  CAS  Google Scholar 

  4. Sobel BE, Gross RW, Robison AK: Thrombolysis, clot selectivity, and kinetics. Circulation 70:160–164, 1984.

    Article  PubMed  CAS  Google Scholar 

  5. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB: Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70:1012–1017, 1984.

    Article  PubMed  CAS  Google Scholar 

  6. Tiefenbrunn AJ, Robison AK, Kurnik PB, Ludbrook PA, Sobel BE: Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 71:110–116, 1985.

    Article  PubMed  CAS  Google Scholar 

  7. Topol EJ, Bell WR, Weisfeldt ML: Coronary thrombolysis with recombinant tissue-type plasminogen activator: hematologic and pharmacologic study. Ann Int Med 103:837–843, 1985.

    PubMed  CAS  Google Scholar 

  8. Hamsten A, Wiman B, deFaire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557–1563, 1985.

    Article  PubMed  CAS  Google Scholar 

  9. Williams DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, Markis JE, Mueller H, Desvigne-Nickens P, Passamani ER, Powers ER, Rao AK, Roberts R, Ross A, Ryan TJ, Sobel BE, Winniford M, Zaret B: Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73(2):338–346, 1986.

    Article  PubMed  CAS  Google Scholar 

  10. Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, Brower RW, de Bono DP, Huhmann W, Lubsen J, Meyer J, Rutsch W, Schmidt W, von Essen R: Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet I:842–847, 1985.

    Article  Google Scholar 

  11. Verstraete M, Brower RW, Collen D, Dunning AJ, Lubsen J, Michel PL, Schofer JS, Vanhaecke J, Van de Werf F, Bleifeld W, Charbonnier B, de Bono DP, Lennane RJ, Mathey DG, Raynaud PH, Vahanian A, Van de Kley GA, Von Essen R: Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet II:965–969, 1985.

    Article  Google Scholar 

  12. The TIMI Study Group: The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 312:932–936, 1985.

    Google Scholar 

  13. Topol EJ, O’Neill WW, Walton JA, Bourdillon PDV, Bates ER, Langburd A, Baumann G, Burney RE, Kline E, Schork MA, Pitt B: Preliminary report of a randomized, placebo controlled trial of recombinant tissue plasminogen activator and emergency coronary angioplasty in acute myocardial infarction. Clin Res 34:349A, 1986.

    Google Scholar 

  14. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I, Collen D: Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73(2): 347–352, 1986.

    Article  PubMed  CAS  Google Scholar 

  15. Rentrop KP: Thrombolytic therapy in patients with acute myocardial infarction. Circulation 71:627–631, 1985.

    Article  PubMed  CAS  Google Scholar 

  16. William DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, Markis JE, Mueller H, Desvigna-Nickens P, Passamani ER, Powers ER, Rao AK, Roberts R, Ross A, Ryan TJ, Sobel BE, Winniford M, Zaret B and Co-investigators. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73:338–346, 1986.

    Article  Google Scholar 

  17. Spann JF, Sherry S: Coronary thrombolysis for evolving myocardial infarction. Drugs 28:465–483, 1984.

    Article  PubMed  CAS  Google Scholar 

  18. Marder VJ, Rothbard RL, Fitzpatrick PG, Francis CW, Smith EK, Rogal GJ: Dose response study of intravenous acylated streptokinase: plasmin complex (BRL26921) in coronary artery thrombosis. Circulation 70(Suppl II):II-29, 1984.

    Google Scholar 

  19. Van de Werf F, Nobuhara M, Collen D: Coronary thrombolysis with human sinqle-chain urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Int Med 104:345–348, 1986.

    PubMed  Google Scholar 

  20. Topol EJ, Herskowitz A, Hutchins G: Massive hemorrhagic myocardial infarction after coronary thrombolysis. Ann J Med 81:(in press), 1986.

    Google Scholar 

  21. Braunwald E, Kloner RA: Myocardial reperfusion: a double-edged sword? J Clin Invest 76:1713–1719, 1985.

    Article  PubMed  CAS  Google Scholar 

  22. Gruppo Italiano Per Lo Studio Delia Streptochinasi Nell’Infarcto Miocardio (GISSI): effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet I:397–401, 1986.

    Google Scholar 

  23. Simoons ML, Brand M V/D, de Zwaan C, Verheugt FWA, Remme WJ, Serruys PW, Bar F, Res J, Krauss XH, Vermeer F: Improved survival after early thrombolysis in acute myocardial infarction. Lancet II:578–582, 1985.

    Article  Google Scholar 

  24. Nobuyoshi M, Nosaka H, Yasumoto H: Can intracoronary thrombolysis prevent free wall rupture of acute myocardial infarction? JACC 7: (2) 107A, 1986.

    Google Scholar 

  25. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M): mortality, morbitidy and infarct size at 21 days. N Engl J Med 314:1465–1471, 1986.

    Article  Google Scholar 

  26. Schmidt WG, Essen RV, Uebis R, Effert S, Rutsch W, Schartl M, Schmutzler H, Erbel R, Meyer J: Thrombolytic treatment of acute myocardial infarction with recombinant-tissue type plasminogen activator: coronary state after 4 weeks. J Am Coll Cardiol 7:16A, 1986.

    Google Scholar 

  27. Krucoff MW, Green CE, Satler LF, Miller FC, Pallas RS, Kent KM, Del Negro AA, Pearle DL, Fletcher RD, Rackley CE: Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. Am J Cardiol 57:916–922, 1986.

    Article  PubMed  CAS  Google Scholar 

  28. Kircher B, Topol EJ, Schork MA, Kline E, Pitt B, O’Neill W: Noninvasive prediction of infarct vessel recanalization status after intravenous tissue plasminogen activator or streptokinase. Clin Res 34:315A, 1986.

    Google Scholar 

  29. Sobel BE, Fields LE, Robison AK, Fox KAA, Sarnoff SJ: Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator. Proc Natl Acad Sci 82:4258–4262, 1985.

    Article  PubMed  CAS  Google Scholar 

  30. Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR: Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72(6):1346–1354, 1985.

    Article  PubMed  CAS  Google Scholar 

  31. Clouse LH, Comp PC: The regulation of hemostasis: the protein C system. N Engl J Med 314:1298–1304, 1986.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Eric J. Topol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Califf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center, Durham, North Carolina, USA

    Robert M. Califf M.D.  & Galen S. Wagner  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Topol, E.J., Califf, R.M. (1987). The Role of Tissue Plasminogen Activator in Myocardial Infarction. In: Califf, R.M., Wagner, G.S. (eds) Acute Coronary Care 1987. Acute Coronary Care Updates, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2337-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2337-2_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9435-1

  • Online ISBN: 978-1-4613-2337-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation